236 related articles for article (PubMed ID: 37353799)
1. Cuproptosis engages in c-Myc-mediated breast cancer stemness.
Wang R; Xu K; Chen Q; Hu Q; Zhang J; Guan X
J Transl Med; 2023 Jun; 21(1):409. PubMed ID: 37353799
[TBL] [Abstract][Full Text] [Related]
2. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.
Gupta N; Jung K; Wu C; Alshareef A; Alqahtani H; Damaraju S; Mackey JR; Ghosh S; Sabri S; Abdulkarim BS; Bigras G; Lai R
Oncotarget; 2017 Apr; 8(17):28101-28115. PubMed ID: 28427212
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
4. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.
Gao X; Liu X; Lu Y; Wang Y; Cao W; Liu X; Hu H; Wang H
Breast Cancer; 2019 Sep; 26(5):663-671. PubMed ID: 30989585
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
Front Genet; 2022; 13():939956. PubMed ID: 36105090
[No Abstract] [Full Text] [Related]
6. Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.
Yang F; Cao L; Sun Z; Jin J; Fang H; Zhang W; Guan X
Int J Biol Sci; 2016; 12(12):1568-1577. PubMed ID: 27994520
[TBL] [Abstract][Full Text] [Related]
7. Emerging roles of Myc in stem cell biology and novel tumor therapies.
Yoshida GJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):173. PubMed ID: 30053872
[TBL] [Abstract][Full Text] [Related]
8. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/c-MYC Axis Promotes the Acquisition of Cancer Stem-Like Features in Esophageal Squamous Cell Carcinoma.
Zhang HF; Wu C; Alshareef A; Gupta N; Zhao Q; Xu XE; Jiao JW; Li EM; Xu LY; Lai R
Stem Cells; 2016 Aug; 34(8):2040-51. PubMed ID: 27144349
[TBL] [Abstract][Full Text] [Related]
10. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway.
Zhu W; Niu J; He M; Zhang L; Lv X; Liu F; Jiang L; Zhang J; Yu Z; Zhao L; Bi J; Yan Y; Wei Q; Huo H; Fan Y; Chen Y; Ding J; Wei M
J Transl Med; 2019 Aug; 17(1):259. PubMed ID: 31395064
[TBL] [Abstract][Full Text] [Related]
11. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133+ Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways.
Shen C; Chen F; Wang H; Li G; Yu C; Wang X; Wen Z
Cell Physiol Biochem; 2018; 49(1):282-294. PubMed ID: 30138944
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
13. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
14. MYC dysfunction modulates stemness and tumorigenesis in breast cancer.
Liu Y; Zhu C; Tang L; Chen Q; Guan N; Xu K; Guan X
Int J Biol Sci; 2021; 17(1):178-187. PubMed ID: 33390842
[TBL] [Abstract][Full Text] [Related]
15. A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis.
Ozsvari B; Sotgia F; Lisanti MP
Aging (Albany NY); 2017 Oct; 9(10):2098-2116. PubMed ID: 29080556
[TBL] [Abstract][Full Text] [Related]
16. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
Ma F; Liu X; Zhou S; Li W; Liu C; Chadwick M; Qian C
Cancer Lett; 2019 May; 450():63-75. PubMed ID: 30771425
[TBL] [Abstract][Full Text] [Related]
18. Breast tumour cell subpopulations with expression of the MYC and OCT4 proteins.
Litviakov NV; Bychkov VA; Stakheeva MN; Ibragimova MK; Tsyganov MM; Gaptulbarova KA; Tashireva LA; Bondar LN; Garbukov EY; Slonimskaya EM
J Mol Histol; 2020 Dec; 51(6):717-728. PubMed ID: 33037978
[TBL] [Abstract][Full Text] [Related]
19. Triterpene Acid (
Choi HS; Kim SL; Kim JH; Deng HY; Yun BS; Lee DS
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149665
[TBL] [Abstract][Full Text] [Related]
20. CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β -catenin Signaling.
Peng F; Yang C; Kong Y; Huang X; Chen Y; Zhou Y; Xie X; Liu P
Curr Cancer Drug Targets; 2020; 20(2):156-165. PubMed ID: 31744448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
